Cansino Biologics, Inc. Class ASSE: 688185

Voluntary Disclosure on the Approval of Clinical Trial for Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) in Indonesia

· Issued by Cansino Biologics, Inc. Class A via Shanghai Stock Exchange
Voluntary Disclosure on the Approval of Clinical Trial for Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) in Indonesia

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment